|
74 Companies |
|
57 Products |
|
57 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
680 News |
|
| «12...234567891011121314» |
- Enrollment change, IO biomarker: Interferon Responses in Eczema Herpeticum (clinicaltrials.gov) - Apr 13, 2014
P=N/A, N=120, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=75 --> 120
- ||||| HSV vaccine (GEN-003) / Genocea, Shionogi
New P2 trial: Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - Apr 13, 2014
P2, N=300, Not yet recruiting, Sponsor: Genocea Biosciences, Inc.
- Enrollment open: AENEASII: Exhaled Breath Analysis in the Early Detection of Aspergillosis (clinicaltrials.gov) - Apr 7, 2014
P=N/A, N=150, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
N=75 --> 120 Not yet recruiting --> Recruiting
- | gentamicin sulfate / Generic mfg.
Enrollment open: Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama (clinicaltrials.gov) - Apr 7, 2014
P3, N=300, Recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
Not yet recruiting --> Recruiting Suspended --> Recruiting
- | CLS003 / Maruho
Biomarker, New P1/2 trial: First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts (clinicaltrials.gov) - Apr 6, 2014
P1/2, N=12, Recruiting, Sponsor: Cutanea Life Sciences, Inc.
- | CLS003 / Maruho
Biomarker, Enrollment open: First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts (clinicaltrials.gov) - Apr 2, 2014
P1/2, N=12, Recruiting, Sponsor: Cutanea Life Sciences, Inc.
Suspended --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers (clinicaltrials.gov) - Apr 1, 2014
P1, N=36, Recruiting, Sponsor: Infectious Disease Research Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- cefazolin / Generic mfg.
Trial initiation date: DAD: Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion (clinicaltrials.gov) - Mar 31, 2014
P1, N=0, Available, Sponsor: Silberg, Barry N., M.D.
Not yet recruiting --> Recruiting Initiation date: Mar 2008 --> Jan 2014
- New P1/2 trial: Efficacy and Safety of Silk Fibroin With Bioactive Coating Layer Dressing (clinicaltrials.gov) - Mar 17, 2014
P1/2, N=30, Recruiting, Sponsor: Chulalongkorn University
- | Xepi (ozenoxacin) / Maruho, Cipher, Ferrer International
New P3 trial: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo (clinicaltrials.gov) - Mar 16, 2014
P3, N=0, Not yet recruiting, Sponsor: Ferrer Internacional S.A.
- || Altabax (retapamulin) / GSK, Almirall
Enrollment change: ALTARGOPMS: ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) (clinicaltrials.gov) - Mar 12, 2014
P=N/A, N=3000, Recruiting, Sponsor: GlaxoSmithKline
Initiation date: Mar 2008 --> Jan 2014 N=4500 --> 3000
- Decadron (dexamethasone) / Merck (MSD)
Clinical: Use of Corticosteroids in Children With Cellulitis (clinicaltrials.gov) - Mar 12, 2014
P=N/A, N=124, Not yet recruiting, Sponsor: Hospital General de Niños Pedro de Elizalde
- Enrollment open: Pharmacokinetics of Miltefosine in Children and Adults (clinicaltrials.gov) - Mar 10, 2014
P4, N=60, Recruiting, Sponsor: Centro Internacional de Entrenamiento e Investigaciones Médicas
N=4500 --> 3000 Not yet recruiting --> Recruiting
- | pentoxifylline / Generic mfg.
Enrollment open, IO biomarker, Immunomodulating: Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis (clinicaltrials.gov) - Mar 10, 2014
P2/3, N=100, Recruiting, Sponsor: Centro Internacional de Entrenamiento e Investigaciones M
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | otesaconazole (VT-1161) / Mycovia Pharma
Enrollment closed: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis (clinicaltrials.gov) - Mar 9, 2014
P2, N=48, Active, not recruiting, Sponsor: Viamet Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- valacyclovir / Generic mfg., acyclovir / Generic mfg.
Trial completion: ACV-VAL: Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons (clinicaltrials.gov) - Mar 9, 2014
P4, N=32, Completed, Sponsor: University of Washington
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- brilacidin (PMX-30063) / Innovation Pharma
Enrollment open: Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections (clinicaltrials.gov) - Mar 5, 2014
P2, N=215, Enrolling by invitation, Sponsor: Cellceutix Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- || albendazole / Generic mfg.
New P3 trial: Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana (clinicaltrials.gov) - Mar 2, 2014
P3, N=375, Not yet recruiting, Sponsor: University Hospital Case Medical Center
- New P1 trial: Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers (clinicaltrials.gov) - Feb 24, 2014
P1, N=36, Recruiting, Sponsor: Infectious Disease Research Institute
- |||| Trial completion: Study With a Topical Gel to Treat Common Warts in Adults (clinicaltrials.gov) - Feb 22, 2014
P2, N=88, Completed, Sponsor: Graceway Pharmaceuticals, LLC
Not yet recruiting --> Enrolling by invitation No longer recruiting --> Completed
- | Trial completion: Study With a Topical Gel to Treat Common Warts in Adults (clinicaltrials.gov) - Feb 22, 2014
P2, N=48, Completed, Sponsor: Graceway Pharmaceuticals, LLC
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| griseofulvin / Generic mfg., terbinafine HCL / Generic mfg.
Trial completion: Terbinafine Compared to Griseofulvin in Children With Tinea Capitis (clinicaltrials.gov) - Feb 22, 2014
P3, N=720, Completed, Sponsor: Novartis
No longer recruiting --> Completed Recruiting --> Completed
- |||| Trial completion: Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects (clinicaltrials.gov) - Feb 22, 2014
P2, N=84, Completed, Sponsor: Graceway Pharmaceuticals, LLC
Recruiting --> Completed No longer recruiting --> Completed
- |||| Trial completion: An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects (clinicaltrials.gov) - Feb 22, 2014
P2, N=84, Completed, Sponsor: Graceway Pharmaceuticals, LLC
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| Trial completion: Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults (clinicaltrials.gov) - Feb 22, 2014
P2, N=88, Completed, Sponsor: Graceway Pharmaceuticals, LLC
No longer recruiting --> Completed No longer recruiting --> Completed
- | Arbelic (telavancin) / Cumberland
Trial completion, Gram positive: ATLAS2: Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus (clinicaltrials.gov) - Feb 22, 2014
P3, N=1035, Completed, Sponsor: Theravance, Inc.
No longer recruiting --> Completed Recruiting --> Completed
- | Arbelic (telavancin) / Cumberland
Trial completion, Gram positive: ATLAS1: Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus (clinicaltrials.gov) - Feb 22, 2014
P3, N=862, Completed, Sponsor: Theravance, Inc.
Recruiting --> Completed Recruiting --> Completed
- || amphotericin b liposome / Generic mfg.
Trial completion: A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). (clinicaltrials.gov) - Feb 22, 2014
P2/3, N=30, Completed, Sponsor: Pfizer
Recruiting --> Completed No longer recruiting --> Completed
- | ketoconazole / Generic mfg., ciclopirox topical / Generic mfg.
Trial completion: Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm) (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=47, Completed, Sponsor: Chen, Catherine, M.D.
No longer recruiting --> Completed Recruiting --> Completed
- | Trial completion: Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis (clinicaltrials.gov) - Feb 22, 2014
P1, N=45, Completed, Sponsor: Infectious Disease Research Institute
Recruiting --> Completed No longer recruiting --> Completed
- | Trial completion, Combination therapy: Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis (clinicaltrials.gov) - Feb 22, 2014
P1, N=48, Completed, Sponsor: Infectious Disease Research Institute
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| famciclovir / Generic mfg.
Trial completion: Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection (clinicaltrials.gov) - Feb 22, 2014
P3, N=74, Completed, Sponsor: Novartis Pharmaceuticals
No longer recruiting --> Completed Recruiting --> Completed
- | valacyclovir / Generic mfg.
Trial completion: Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir (clinicaltrials.gov) - Feb 22, 2014
P3, N=91, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- | acyclovir / Generic mfg.
Trial completion: Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates (clinicaltrials.gov) - Feb 22, 2014
P3, N=46, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | acyclovir / Generic mfg.
Trial completion: Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth (clinicaltrials.gov) - Feb 22, 2014
P3, N=29, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients (clinicaltrials.gov) - Feb 20, 2014
P=N/A, N=200, Completed, Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Active, not recruiting --> Completed Recruiting --> Completed
- | itraconazole / Generic mfg.
Trial completion: A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=96, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed No longer recruiting --> Completed
- | acyclovir / Generic mfg.
Trial completion: Herpetic Eye Disease Study (HEDS) II (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: National Eye Institute (NEI)
No longer recruiting --> Completed No longer recruiting --> Completed
- phenoxymethylpenicillin / Generic mfg., doxycycline / Generic mfg., amoxicillin / Generic mfg.
Enrollment closed: NorTick_EM: Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice (clinicaltrials.gov) - Feb 12, 2014
P4, N=225, Active, not recruiting, Sponsor: Morten Lindbaek
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- || Enrollment closed: Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis (clinicaltrials.gov) - Feb 9, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- amoxicillin / Generic mfg.
Trial termination, Head-to-Head: Short Course of Amoxicillin for Erysipelas (clinicaltrials.gov) - Feb 5, 2014
P4, N=10, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Terminated; Insufficient number of inclusion
- amoxicillin / Generic mfg.
Trial initiation date, Head-to-Head: Short Course of Amoxicillin for Erysipelas (clinicaltrials.gov) - Feb 5, 2014
P4, N=10, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Terminated; Insufficient number of inclusion Initiation date: Feb 2010 --> Sep 2010
- amoxicillin / Generic mfg.
Enrollment change, Head-to-Head: Short Course of Amoxicillin for Erysipelas (clinicaltrials.gov) - Feb 5, 2014
P4, N=10, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
Initiation date: Feb 2010 --> Sep 2010 N=646 --> 10
- Enrollment open: Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia (clinicaltrials.gov) - Feb 3, 2014
P1/2, N=80, Recruiting, Sponsor: Drugs for Neglected Diseases
N=646 --> 10 Not yet recruiting --> Recruiting
- Kineret (anakinra) / SOBI
Enrollment closed: Anakinra in Hidradenitis Suppurativa (clinicaltrials.gov) - Feb 2, 2014
P2, N=20, Active, not recruiting, Sponsor: University of Athens
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | brilacidin (PMX-30063) / Innovation Pharma
New P2 trial: Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections (clinicaltrials.gov) - Jan 30, 2014
P2, N=215, Enrolling by invitation, Sponsor: Cellceutix Pharmaceuticals
- ||| Enrollment closed: Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores (clinicaltrials.gov) - Jan 30, 2014
P2, N=480, Active, not recruiting, Sponsor: Topical Remedy
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial termination: Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients (clinicaltrials.gov) - Jan 27, 2014
P=N/A, N=28, Terminated, Sponsor: Federal University of Rio de Janeiro
Recruiting --> Active, not recruiting Recruiting --> Terminated; Low accrual
- Enrollment change: Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients (clinicaltrials.gov) - Jan 27, 2014
P=N/A, N=28, Terminated, Sponsor: Federal University of Rio de Janeiro
Recruiting --> Terminated; Low accrual N=105 --> 28
- ||||||| Naftin (naftifine hydrochloride) / Merz Pharma
Trial completion: Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris (clinicaltrials.gov) - Jan 23, 2014
P3, N=65, Completed, Sponsor: Merz Pharmaceuticals, LLC
N=105 --> 28 Active, not recruiting --> Completed